Mesoblast (NASDAQ:MESO) Trading Down 2.4% – Here’s Why

Mesoblast Limited (NASDAQ:MESO)’s stock price traded down 2.4% during mid-day trading on Wednesday . The company traded as low as $9.36 and last traded at $9.39. 7,622 shares were traded during trading, a decline of 99% from the average session volume of 828,979 shares. The stock had previously closed at $9.62.

Analyst Ratings Changes

MESO has been the subject of a number of research reports. Maxim Group upgraded shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a report on Tuesday, September 24th. Piper Sandler raised Mesoblast from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $4.00 to $11.00 in a research report on Tuesday, July 23rd. Jefferies Financial Group upgraded shares of Mesoblast from a “hold” rating to a “buy” rating in a research note on Thursday, August 29th. Cantor Fitzgerald restated an “overweight” rating on shares of Mesoblast in a report on Thursday, August 29th. Finally, StockNews.com cut Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Mesoblast has an average rating of “Moderate Buy” and an average target price of $11.50.

Mesoblast Stock Performance

The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -8.59 and a beta of 3.47. The firm has a 50-day simple moving average of $7.13 and a 200 day simple moving average of $7.01.

Hedge Funds Weigh In On Mesoblast

A number of hedge funds and other institutional investors have recently bought and sold shares of MESO. Marshall Wace LLP purchased a new stake in shares of Mesoblast in the second quarter valued at about $562,000. Chase Investment Counsel Corp acquired a new stake in shares of Mesoblast in the first quarter valued at about $298,000. Lazari Capital Management Inc. grew its position in Mesoblast by 6.6% during the second quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company’s stock worth $364,000 after buying an additional 3,300 shares during the period. Creative Planning acquired a new stake in shares of Mesoblast during the 3rd quarter valued at approximately $147,000. Finally, XTX Topco Ltd purchased a new stake in shares of Mesoblast during the 2nd quarter worth approximately $103,000. 1.43% of the stock is currently owned by hedge funds and other institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.